Close Menu

Cell Biosciences

A year ago, the Santa Clara, Calif.-based nano-proteomics technology development company was preparing its first commercial launch. The Protein Forest deal is the second purchase in recent months for the company, which is still on the lookout to add to its portfolio.

In connection with the acquisition, Cell Biosciences raised an additional $4 million in equity financing.

Cell Biosciences will pay Alpha Innotech's shareholders $1.50 per share, giving the deal a total consideration of $17.9 million.

For a firm that launched its first product commercially only five months ago, the proposed deal represents a major move to grow its footprint. Just over a year ago, Cell Biosciences underwent a total reorganization in its management to segue from being a technology startup to a company focused on commercializing its products

The deal provides Cell Biosciences with complementary protein analysis products.

The CB1000 is the company's maiden commercial launch and comes amid a tumultuous year in which changes took place in top management.

Cell Biosciences will use funding to pursue commercialization of its proteomics analysis system.

The university will use the system in its stem cell and leukemia proteomics studies.


The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.